- Home
- TRTX vs TYRA Comparison
TRTX vs TYRA Comparison
Compare TRTX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- TYRA
- Stock Information
- Founded
- TRTX 2014
- TYRA 2018
- Country
- TRTX United States
- TYRA United States
- Employees
- TRTX N/A
- TYRA 38
- Industry
- TRTX Real Estate Investment Trusts
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- TYRA Health Care
- Exchange
- TRTX Nasdaq
- TYRA Nasdaq
- Market Cap
- TRTX 718.6M
- TYRA 666.4M
- IPO Year
- TRTX 2017
- TYRA 2021
- Fundamental
- Price
- TRTX $8.32
- TYRA $13.17
- Analyst Decision
- TRTX Buy
- TYRA Strong Buy
- Analyst Count
- TRTX 6
- TYRA 6
- Target Price
- TRTX $8.92
- TYRA $30.50
- AVG Volume (30 Days)
- TRTX 464.4K
- TYRA 247.2K
- Earning Date
- TRTX 02-18-2025
- TYRA 03-18-2025
- Dividend Yield
- TRTX 11.54%
- TYRA N/A
- EPS Growth
- TRTX N/A
- TYRA N/A
- EPS
- TRTX 0.75
- TYRA N/A
- Revenue
- TRTX $148,968,000.00
- TYRA N/A
- Revenue This Year
- TRTX N/A
- TYRA N/A
- Revenue Next Year
- TRTX $3.60
- TYRA N/A
- P/E Ratio
- TRTX $11.13
- TYRA N/A
- Revenue Growth
- TRTX N/A
- TYRA N/A
- 52 Week Low
- TRTX $6.74
- TYRA $11.89
- 52 Week High
- TRTX $9.66
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- TRTX 42.45
- TYRA 43.64
- Support Level
- TRTX $7.98
- TYRA $12.27
- Resistance Level
- TRTX $8.75
- TYRA $13.79
- Average True Range (ATR)
- TRTX 0.19
- TYRA 0.71
- MACD
- TRTX -0.02
- TYRA 0.03
- Stochastic Oscillator
- TRTX 43.51
- TYRA 51.09
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).